Cider, the French communications and pharmaceutical promotion specialist group, is preparing to take a 51% stake in its UK counterpart, Halliday Jones, and a 15% share in a Japanese equivalent, Nihon Pharma Promotion. Cider's president, Jacques Faggianelli, said he hopes both sets of negotiations would culminate in Cider's presence in these markets by the end of the year.
The overall strategy is to double the size of Cider in five years through foreign acquisitions. Cider already represents Halliday Jones in several countries. The UK company is involved in the recruitment, training and supply of medical representatives for drug companies.
The Japanese deal, if successful, would allow Cider within three years to set up a promotion company working for drugmakers other than Japanese enterprises and in which the French group would have a majority stake with NPP holding 49% of the equity. The French company expects a rise of 16% in 1995 sales to 380 million French francs ($70 million), with net profits up 30% at 12 million francs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze